Company / Gross Profit
GYRE THERAPEUTICS, INC. Gross Profit History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$101.9M
FY2024
5-year range
$97.5M / $101.9M
FY2022-FY2024
Trend
+4.5%
vs FY2023
Sector context
#26 of 29
Health Care
What the data says
Among 29 Health Care companies, GYRE THERAPEUTICS, INC. is in the bottom 10% for gross profit. Gross Profit remained relatively stable over the past 3 years, with values between $97M and $102M.
Based on SEC 10-K filings.
$102M in FY2024.
Improved from $97M to $102M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 29This company $101.9M Sector average $3.5B
▼
-97.1% below sector average
Key checks
Key Insights
- In FY2024, gross profit increased 4.5% year-over-year.
- Ranks #26 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $101.9M | +4.5% |
| FY2023 | $97.5M | +0.0% |
| FY2022 | $97.5M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026